Cantargia team


Over 100 years of experience of successful pharmaceutical development

Our management group is made up of people with extensive experience of research and pharmaceutical development from both large and small companies. We also have considerable experience in business development with previous experience of licensing pharmaceutical projects.

Our collective experience includes involvement in more than 10 studies that have resulted in registration, responsibility for a large number of successful phase II and phase III trials and participation in about 20 meetings with the FDA. Members of the management group have been responsible for three major licence deals for phase III products in the field of oncology.

Close cooperation between management, founders and our in-house and external experts means that we are able to work effectively not only on development of our own projects, but also on scientific advances and business development. Work is done in close cooperation with an administrative board with extensive experience within our specialised area.


Goran F1

Göran Forsberg, CEO

Bengt Joendell 01

Bengt Jöndell, CFO

Liselotte L1

Liselotte Larsson, VP Operations, responsible for CMC development and GMP-manufacturing

Lars T1

Lars Thorsson, VP Clinical Development, responsible for clinical development

David L1

David Liberg, VP Cancer Research, responsible for pre-clinical development

Susanne Magnusson Januari 2017

Susanne Magnusson, Associate Director Development

Camilla Rydberg Millrud 03 Edited

Camilla Rydberg Millrud, Project Manager Pre Clinical

Gabriel2

Gabriel Svensson Birkedal, Senior Scientist Protein Chemistry, CMC

Thoas F1

Thoas Fioretos, founder and scientific advisor

Marcus J1

Marcus Järås, founder and scientific advisor

Kjell S

Kjell Sjöström, Innovagen, founder, biochemical development

Karin W1

Karin Von Wachenfeldt, translational research

Peter Holm Januari 2017

Peter Holm, patents and intellectual property